Intellia Therapeutics Inc NTLA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$11.35 up $0.25, 2.25% at close Nov 6
Last close · Previous close $11.10
- Market cap
- $1.59BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.35Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$11.35up $0.25, 2.25%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$11.10Nov 5
- Volume4.40MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume4.59MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $7.95 to $18.48; now $11.35
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NTLA beat the S&P 500 in 2 of 7 periods.
| Period | NTLA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NTLA: down 8.2% S&P 500: down 5.6% | NTLA trailed the S&P 500 by 2.6 percentage points Trailed |
| 3M | NTLA: up 1.0% S&P 500: down 4.1% | NTLA beat the S&P 500 by 5.1 percentage points Beat |
| YTD | NTLA: up 26.3% S&P 500: up 8.7% | NTLA beat the S&P 500 by 17.6 percentage points Beat |
| 1Y | NTLA: down 7.9% S&P 500: up 10.9% | NTLA trailed the S&P 500 by 18.8 percentage points Trailed |
| Long term | ||
| 3Y | NTLA: down 59.0% S&P 500: up 75.0% −25.7% vs +20.5% a year | NTLA trailed the S&P 500 by 134.0 percentage points Trailed |
| 5Y | NTLA: down 91.6% S&P 500: up 67.8% −39.1% vs +10.9% a year | NTLA trailed the S&P 500 by 159.4 percentage points Trailed |
| 10Y | NTLA: down 18.5% S&P 500: up 313.1% −2.0% vs +15.2% a year | NTLA trailed the S&P 500 by 331.6 percentage points Trailed |
$10,000 invested in NTLA 10 years ago (Nov 4, 2016) would be worth about $8,148 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
NTLA beat the S&P 500 in 2 of 7 periods.
| Period | NTLA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NTLA: down 8.2% S&P 500: down 5.6% | NTLA trailed the S&P 500 by 2.6 percentage points Trailed |
| 3M | NTLA: up 1.0% S&P 500: down 4.3% | NTLA beat the S&P 500 by 5.3 percentage points Beat |
| YTD | NTLA: up 26.3% S&P 500: up 7.8% | NTLA beat the S&P 500 by 18.5 percentage points Beat |
| 1Y | NTLA: down 7.9% S&P 500: up 9.7% | NTLA trailed the S&P 500 by 17.6 percentage points Trailed |
| Long term | ||
| 3Y | NTLA: down 59.0% S&P 500: up 68.8% −25.7% vs +19.1% a year | NTLA trailed the S&P 500 by 127.8 percentage points Trailed |
| 5Y | NTLA: down 91.6% S&P 500: up 56.9% −39.1% vs +9.4% a year | NTLA trailed the S&P 500 by 148.5 percentage points Trailed |
| 10Y | NTLA: down 18.5% S&P 500: up 252.6% −2.0% vs +13.4% a year | NTLA trailed the S&P 500 by 271.1 percentage points Trailed |
$10,000 invested in NTLA 10 years ago (Nov 4, 2016) would be worth about $8,148 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$176.78
Closing high on . Now 93.6% below that record.
Split-adjusted daily closes since May 6, 2016.
Stock splits
NTLA hasn’t split since its price history begins in 2016.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$3.35 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 26.7×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 2.2×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −21.98%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.22BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own NTLA DCF in Excel. Value Intellia Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $59.51Mup 12.6%
- Net income
- −$399.98M
- Diluted EPS
- −$3.35
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $9.11M | −$135.71M | −$1.34 |
| Q4 FY24 (Dec 31, 2024) | $12.87M | −$128.90M | −$1.26 |
| Q1 FY25 (Mar 31, 2025) | $16.63M | −$114.33M | −$1.10 |
| Q2 FY25 (Jun 30, 2025) | $14.25M | −$101.26M | −$0.98 |
| Q3 FY25 (Sep 30, 2025) | $13.78M | −$101.32M | −$0.92 |
| Q4 FY25 (Dec 31, 2025) | $23.02M | −$95.79M | −$0.82 |
| Q1 FY26 (Mar 31, 2026) | $15.05M | −$96.23M | −$0.81 |
| Q2 FY26 (Jun 30, 2026) | $7.66M | −$106.63M | −$0.80 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $33.05M | −$267.89M | −$3.78 |
| FY22 (Dec 31, 2022) | $52.12M | −$474.19M | −$6.16 |
| FY23 (Dec 31, 2023) | $36.28M | −$481.19M | −$5.42 |
| FY24 (Dec 31, 2024) | $57.88M | −$519.02M | −$5.25 |
| FY25 (Dec 31, 2025) | $67.67M | −$412.69M | −$3.81 |
Margins
- Gross 100.0%
- Operating −711.7%
- Net −672.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$348.60MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$346.64MLast 12 months
- Capital spending$1.95MLast 12 months
- −585.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $343.65MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $666.08MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$73.41MAs of Jun 30, 2026
- Net cash$592.67MAs of Jun 30, 2026
- 6.65As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.10As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −57.8%Last 12 months
Over the last 12 months, Intellia Therapeutics lost money: its net loss was 57.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −47.3%Last 12 months
Over the last 12 months, Intellia Therapeutics’s net loss was 47.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
NTLA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NTLA stock FAQ
What is NTLA stock’s price today?
Intellia Therapeutics (NTLA) traded at $11.35 at the close on , up $0.25 (2.25%) from the previous close of $11.10. Over the past 52 weeks it has traded between $7.95 and $18.48.
If you invested $1,000 in NTLA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NTLA on would be worth about $815 at the close on , a total return of −18.5%. The same $1,000 would be worth $84 if invested five years ago and $921 if invested one year ago. Past performance doesn’t predict future returns.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market capitalization is about $1.6 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $11.35 (how market cap works). Intellia Therapeutics reported 139.72M shares outstanding at the end of its latest quarter ().
What is NTLA’s P/E ratio?
NTLA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.35).
How much revenue does Intellia Therapeutics make?
Intellia Therapeutics reported $59.5 million of revenue over the four quarters to , up 12.6% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $7.7 million, down 46.2% from a year earlier.
Is Intellia Therapeutics profitable?
Not over the four quarters to . Intellia Therapeutics reported a net loss of $400.0 million across those four quarters on $59.5 million of revenue.
What are NTLA’s earnings per share?
NTLA’s diluted earnings per share were −$3.35 over the four quarters to , compared with −$4.68 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.80 per share, against −$0.98 a year earlier (how EPS works).
Does NTLA pay a dividend?
Intellia Therapeutics hasn’t paid a dividend in the last twelve months.
What is NTLA’s 52-week high and low?
Over the past 52 weeks NTLA has traded as low as $7.95 and as high as $18.48. At $11.35 at the close on , it is 38.6% below that high and 42.8% above the low.
What is NTLA’s all-time high?
NTLA’s highest closing price was $176.78 on , adjusted for stock splits. At $11.35 at the close on , it is 93.6% below that record.
Has NTLA stock ever split?
No. NTLA hasn’t split since its price history begins in 2016.
How has NTLA stock performed?
Including dividends and measured to the close on , NTLA has returned +26.3% so far this year and −7.9% over the past year, and −91.6% over five years (−39.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Intellia Therapeutics in?
Intellia Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does NTLA trade on?
Intellia Therapeutics trades on the Nasdaq under the ticker symbol NTLA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.